Recent Research Analysts’ Ratings Changes for Madrigal Pharmaceuticals (MDGL)

A number of firms have modified their ratings and price targets on shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) recently:

  • 11/12/2026 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
  • 11/7/2026 – Madrigal Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
  • 11/4/2026 – Madrigal Pharmaceuticals is now covered by HC Wainwright. They set a “strong-buy” rating on the stock.
  • 11/4/2026 – Madrigal Pharmaceuticals had its price target raised by Canaccord Genuity Group from $612.00 to $633.00. They now have a “buy” rating on the stock.
  • 11/4/2026 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by Truist Financial. They now have a $743.00 price target on the stock, up from $709.00.
  • 11/3/2026 – Madrigal Pharmaceuticals had its price target raised by Citigroup from $725.00 to $760.00. They now have a “buy” rating on the stock.
  • 10/15/2026 – Madrigal Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/14/2026 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by UBS Group. They now have a $735.00 price target on the stock.
  • 9/24/2026 – Madrigal Pharmaceuticals is now covered by The Goldman Sachs Group. They set a “buy” rating and a $704.00 price target on the stock.
  • 9/24/2026 – Madrigal Pharmaceuticals is now covered by The Goldman Sachs Group. They set a “buy” rating and a $704.00 price target on the stock.
  • 9/23/2026 – Madrigal Pharmaceuticals is now covered by Citigroup. They set a “buy” rating and a $725.00 price target on the stock.
  • 9/23/2026 – Madrigal Pharmaceuticals is now covered by Citigroup. They set a “buy” rating and a $725.00 price target on the stock.

Madrigal Pharmaceuticals Stock Down 0.5%

MDGL stock opened at $421.99 on Wednesday. Madrigal Pharmaceuticals, Inc. has a twelve month low of $353.54 and a twelve month high of $615.00. The company has a quick ratio of 2.78, a current ratio of 3.05 and a debt-to-equity ratio of 0.54. The stock has a market cap of $9.80 billion, a P/E ratio of -70.57 and a beta of -0.98. The business’s 50-day moving average price is $471.14 and its 200-day moving average price is $495.06.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $2.92. The company had revenue of $431.27 million during the quarter, compared to the consensus estimate of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. During the same period in the previous year, the company posted ($5.08) EPS. On average, equities research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -2.08 EPS for the current year.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, CEO William Sibold sold 6,362 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total value of $3,407,423.58. Following the completion of the transaction, the chief executive officer directly owned 202,967 shares in the company, valued at $108,707,095.53. This represents a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bros. Advisors Lp Baker purchased 76,140 shares of the company’s stock in a transaction on Friday, November 6th. The stock was purchased at an average price of $384.32 per share, with a total value of $29,262,124.80. Following the completion of the transaction, the director owned 2,040,682 shares of the company’s stock, valued at approximately $784,274,906.24. This trade represents a 3.88% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 12,660 shares of company stock valued at $6,670,042 over the last 90 days. 17.60% of the stock is currently owned by corporate insiders.

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania. Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Read More

Receive News & Ratings for Madrigal Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.